News
Nuvalent receives U.S. FDA breakthrough therapy designation for NVL-655
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) to Nuvalent's NVL-655 for the treatment of patients with locally advanced or...
Collaboration between Galapagos and Blood Centers of America to improve patient access to life-saving...
Galapagos and Blood Centers of America (BCA) have entered into a strategic collaboration for the decentralized manufacturing of Galapagos’ CAR-T cell therapies through BCA’s...
WHO prequalifies new dengue vaccine
A new vaccine for dengue has received prequalification from the World Health Organization (WHO). TAK-003 is the second dengue vaccine to be prequalified by...
